Merck withdrew Vioxx due to increased stroke and heart attack risks, prompting global concern.
The European Medicines Agency and FDA are reviewing similar drugs.
Vioxx's withdrawal led to lawsuits in Canada and the US.
Merck faces financial losses and legal battles.
Celebrex and Bextra are under scrutiny for potential risks.
The impact on Merck's earnings is significant.
The recall may affect future drug development.
Legal experts predict a surge in lawsuits against Merck.
Concerns about COX-2 inhibitors persist.
The Vioxx litigation landscape is evolving, with potential for federal consolidation of cases.
